1. Evaluation of the Infinium Methylation 450K technology
- Author
-
Matthieu Defrance, Hélène Denis, François Fuks, Emilie Calonne, Sarah Dedeurwaerder, and Christos Sotiriou
- Subjects
Cancer Research ,Infinium II ,peak-based correction ,Breast Neoplasms ,Computational biology ,Biology ,03 medical and health sciences ,Cytosine ,0302 clinical medicine ,Genetics ,Humans ,Biomedicine ,030304 developmental biology ,Epigenomics ,Oligonucleotide Array Sequence Analysis ,0303 health sciences ,DNA methylation ,epigenetics ,Infinium I ,business.industry ,Genome, Human ,DNA Methylation ,Sciences biomédicales ,bisulfite-based method ,High-Throughput Screening Assays ,Cancérologie ,030220 oncology & carcinogenesis ,epigenomics ,Infinium Methylation 450K ,Illumina Methylation Assay ,Female ,DNA methylome ,business ,Software - Abstract
Studies of DNA methylomes hold enormous promise for biomedicine but are hampered by the technological challenges of analyzing many samples cost-effectively. Recently, a major extension of the previous Infinium HumanMethylation27 BeadChip® (Illumina, Inc. CA, USA), called Infinium HumanMethylation450 (Infinium Methylation 450K; Illumina, Inc. CA, USA) was developed. This upgraded technology is a hybrid of two different chemical assays, the Infinium I and Infinium II assays, allowing (for 12 samples in parallel) assessment of the methylation status of more than 480,000 cytosines distributed over the whole genome. In this article, we evaluate Infinium Methylation 450K on cell lines and tissue samples, highlighting some of its advantages but also some of its limitations. In particular, we compare the methylation values of the Infinium I and Infinium II assays., Journal Article, Research Support, Non-U.S. Gov't, SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2011